Payment overview · 2025
General Payments
$2,663.29
143 reported records · 24 companies
Healthcare provider profile · identity verified
Lance P Criblez, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PANDORA, OH · NPI 1174519342
Verified facts
What the public records show
CMS Open Payments records show Lance P Criblez, M.D. received $2,663.29 in general payments during 2025 across 143 reported records.
AstraZeneca Pharmaceuticals LP accounted for 16.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $443.03 | 16.6% | 18 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $419.79 | 15.8% | 30 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $304.74 | 11.4% | 21 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $232.30 | 8.7% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $222.74 | 8.4% | 12 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $173.09 | 6.5% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $159.29 | 6.0% | 10 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $128.51 | 4.8% | 6 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $77.83 | 2.9% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $76.02 | 2.9% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $61.72 | 2.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $53.56 | 2.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $37.21 | 1.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.15 | 1.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $36.85 | 1.4% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $35.04 | 1.3% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $30.00 | 1.1% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $29.62 | 1.1% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $27.08 | 1.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.60 | 0.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.11 | 0.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.56 | 0.6% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $14.95 | 0.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.50 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,663.29 | 143 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $287.41 | 10 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $251.55 | 16 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $232.30 | 13 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $227.98 | 16 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $217.82 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $181.27 | 12 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $173.09 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $170.60 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $159.29 | 10 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $154.74 | 9 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $133.91 | 8 | 2025 |
Source payment records
|
|||||
| ANDEXXA Normalized: andexxa |
Biological | AstraZeneca Pharmaceuticals LP | $116.40 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $99.15 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $97.73 | 8 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $81.50 | 4 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $77.83 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $76.02 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $74.92 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $64.91 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $64.90 | 5 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $64.90 | 5 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $61.72 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $53.59 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $37.21 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $37.21 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $37.15 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $36.85 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $35.04 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $34.99 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $30.00 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $29.62 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $27.08 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $27.08 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.57 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.60 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.56 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.56 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $14.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 180 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 134 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 108 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
54 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
180 | 25 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
134 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
134 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
78 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
108 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
165 | 29 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Meloxicam | Meloxicam | 399 | 98 |
| Lisinopril | Lisinopril | 303 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 276 | 59 |
| Omeprazole | Omeprazole | 274 | 71 |
| Metformin Hcl | Metformin Hcl | 258 | 70 |
| Atorvastatin Calcium | Atorvastatin Calcium | 244 | 60 |
| Simvastatin | Simvastatin | 237 | 54 |
| Montelukast Sodium | Montelukast Sodium | 227 | 73 |
| Gabapentin | Gabapentin | 211 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 198 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 197 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 187 | 45 |
| Farxiga | Dapagliflozin Propanediol | 180 | 25 |
| Amlodipine Besylate | Amlodipine Besylate | 178 | 37 |
| Sertraline Hcl | Sertraline Hcl | 178 | 40 |
| Prednisone | Prednisone | 172 | 101 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 171 | 38 |
| Potassium Chloride | Potassium Chloride | 168 | 41 |
| Eliquis | Apixaban | 165 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 164 | 42 |
| Furosemide | Furosemide | 161 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 160 | 41 |
| Losartan Potassium | Losartan Potassium | 150 | 32 |
| Pioglitazone Hcl | Pioglitazone Hcl | 143 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 136 | 24 |
| Jardiance | Empagliflozin | 134 | 27 |
| Finasteride | Finasteride | 128 | 23 |
| Tramadol Hcl | Tramadol Hcl | 123 | 29 |
| Ozempic | Semaglutide | 108 | 17 |
| Alprazolam | Alprazolam | 104 | 23 |
| Valsartan | Valsartan | 102 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 100 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 95 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 91 | 16 |
| Bumetanide | Bumetanide | 88 | 20 |
| Xarelto | Rivaroxaban | 85 | 18 |
| Atenolol | Atenolol | 82 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 16 |
| Trulicity | Dulaglutide | 78 | 12 |
| Allopurinol | Allopurinol | 76 | 17 |
| Trazodone Hcl | Trazodone Hcl | 74 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 74 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 72 | 16 |
| Celecoxib | Celecoxib | 71 | 20 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 69 | 12 |
| Donepezil Hcl | Donepezil Hcl | 68 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 23 |
| Spironolactone | Spironolactone | 65 | 16 |
| Azithromycin | Azithromycin | 63 | 55 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 60 | 46 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 60 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 60 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 58 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 58 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 56 | 12 |
| Synthroid | Levothyroxine Sodium | 54 | 14 |
| Metformin Hcl Er | Metformin Hcl | 53 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 51 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | suppressed |
| Methotrexate | Methotrexate Sodium | 47 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 46 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 11 |
| Metolazone | Metolazone | 44 | 19 |
| Mounjaro | Tirzepatide | 44 | suppressed |
| Myrbetriq | Mirabegron | 44 | suppressed |
| Pregabalin | Pregabalin | 44 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 43 | suppressed |
| Memantine Hcl | Memantine Hcl | 42 | suppressed |
| Cefdinir | Cefdinir | 41 | 35 |
| Sucralfate | Sucralfate | 41 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | suppressed |
| Bupropion Xl | Bupropion Hcl | 38 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 37 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Ezetimibe | Ezetimibe | 37 | suppressed |
| Fluconazole | Fluconazole | 37 | 30 |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Levofloxacin | Levofloxacin | 35 | 31 |
| Aripiprazole | Aripiprazole | 33 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | suppressed |
| Repatha Sureclick | Evolocumab | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | 15 |
| Lorazepam | Lorazepam | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | suppressed |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Kerendia | Finerenone | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Famotidine | Famotidine | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Mirabegron Er | Mirabegron | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 11 |
| Cephalexin | Cephalexin | 20 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | 11 |
| Colesevelam Hcl | Colesevelam Hcl | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Febuxostat | Febuxostat | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Carvedilol | Carvedilol | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Ramipril | Ramipril | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 14 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 13 | 13 |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 11 |
| Nadolol | Nadolol | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 12 |
| Acetazolamide | Acetazolamide | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
| Travoprost | Travoprost | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,663.29 · 143 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, ANDEXXA, AREXVY, Auvelity, BREZTRI, CAPLYTA, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Kerendia, LEQVIO, LINZESS, MOUNJARO, NURTEC ODT, OPSUMIT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, Symbravo, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, Tymlos, UBRELVY, UPTRAVI, VOQUEZNA, VRAYLAR, WATCHMAN Access System, Wegovy, XIFAXAN, YUPELRI, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error